The universal second messenger cyclic AMP (cAMP) is generated upon stimulation of Gs protein-coupled receptors, such as the β2-adrenergic receptor (β2-AR), and leads to
Introduction
G protein-coupled receptors, such as the Gs-coupled β2-adrenergic receptor (β2-AR), currently represent one of the largest groups of drug targets (1) . After receptor binding of β2-agonists such as isoprenaline and fenoterol, elevation in the cellular content of cyclic adenosine monophosphate (cAMP) is catalysed by membrane-bound adenylyl cyclases (ACs) (2-4), a process known to be shaped by cAMP-degrading phosphodiesterases (PDEs) (5) (6) (7) (8) (9) . Among the PDE superfamily members, PDE4, PDE7 and PDE8 exhibit substrate specificity towards cAMP (7, 8) .
The best known effector of cAMP is protein kinase A (PKA). The PKA holoenzyme consists of two catalytic (C) subunits, which exist in three isoforms (Cα, Cβ and Cγ), and two regulatory (R) subunits. There are two major isoforms of PKA, designated as PKA(I) and PKA(II), which differ exclusively due to the RI and RII subunits, each again subdivided in an α and β isoform (RIα, RIβ, RIIα, RIIβ). Upon binding of two cAMP molecules to each R subunit, the dimer releases the C subunits and thereby initiates target protein phosphorylation. PKA is known to oscillate between an on and off state and thereby regulates a plethora of cellular responses (10) . With the 52) and hetero-dimers (53), a process initially described for AKAP-Lbc (50). For example, overexpression of AKAP12 in cells that endogenously express AKAP5, such as HEK293 or A431 cells, potentiates AKAP5-mediated phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in response to the β2-agonist isoprenaline (53).
Interestingly, however, AKAP12 mediated recycling of the β2-AR was unaffected upon AKAP5 overexpression (53) (Figure 1) . Thus, oligomerization of AKAP family members may regulate a distinct subset of signalling properties. However, mechanisms involved in AKAP oligomerization, and how such dimer formation is triggered by molecular cues still remain obscure.
For the purpose of this review, we will summarize the most important features of AKAP5, AKAP12, and Ezrin (AKAP78) ( Table 1) . Neuronal key discoveries will be recapitulated to introduce paradigm shifts that illustrate the general spatio-temporal nature of the compartmentalized cAMP signalling. Our goal is to translate the lessons learned from neurons to the lung as our current knowledge about cAMP compartmentalization in the airways is rather limited. Before that, we will focus in the next section on cAMP compartmentalization via AKAPs acting alone with PKA or in concert with Epac, starting in the following section with the different tools currently available or under development.
Tools to study compartmentalization of cAMP
In the following section, we will highlight novel tools used to study the effect of AKAPbearing multiprotein complexes on a diverse subset of biological functions. As some AKAPs bind to Epac in additionto PKA, we will briefly discuss some tools that are used to interfere at the level of PKA or Epac. For further details about Epac, we would like to refer the reader to recent reviews on this topic (13) (14) (15) (16) . Our main focus is the tools that interfere with AKAP-bearing multiprotein complexes. 
Epac and PKA
To distinguish between PKA and Epac, cell membrane-permeable cyclic nucleotide analogues have been developed, such as N 6 -benzyladenosine-3',5'-cyclic monophosphate (6-Bnz-cAMP) for PKA or 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (8-pCPT-2'-O-Me-cAMP) for Epac (15, 54, 55) . In addition, inhibitors of PKA have also been synthesized, such as Rp-8-CPT-cAMPS, and have been shown to abolish the dissociation of PKA-C subunits from the PKA-R subunits (54) . These compounds seem to provide more specificity compared to PKA inhibitors known to act on the ATP binding site, such as H-89 (56 
A-kinase anchoring proteins: Dynamics of PKA and AKAP
To assess the dynamics of the primary AKAP interaction partner PKA in vivo, several fluorescence resonance energy transfer (FRET) tools have been developed taking advantage of genetically encoded A-kinase activity reporters (65) (66) (67) (68) (69) (70) . The addition of cellular localization signals permits the recruitment of these tools to subcellular compartments, including the cytosol, the nucleus, the sarcoplasmic reticulum, the mitochondria (using an AKAP based localization), the plasma membrane (68, 71) 
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In addition, recent studies intend to facilitate a distinction between different AKAPs based on their ability to interact with a discrete interaction partner and/or on mechanisms distinct from the AKAP-PKA interaction outlined earlier. The dominant interfering peptide GSKIPtide, structurally based on the glycogen synthase kinase 3β (GSK3β) binding site of GSK3β interaction protein (GSKIP), competes with AKAP members known to bind to GSK3β, including GSKIP, AKAP11 and MAP2D (in rat) and thereby to disrupt the compartmentalization of GSK3β (82) ( Figure 2B ). Meanwhile, similar peptides were designed, such as a phospholamban peptide, which is able to prevent the interaction with AKAP7δ (83) and EBP50 (also known as NHERF1, SLC9A3R1) peptide which prevents the interaction with Ezrin (AKAP78) (84) ( Table 1) .
Also of particular interest are peptides that specifically inhibit the interaction between mAKAP and the AC isoform 5 (AC5), leaving the interaction between AKAP5-AC5 unaltered (85) . Recently, a disruptor for the Hsp20-PDE4 interaction has been described that liberates PDE4 from the AKAP-Lbc based complex (86) .
Most tools being developed thus far, however, are still peptide based and might therefore exert some unknown interactions. For example, it has been reported that stHt31P, generated from st-Ht31 by two proline substitutions believed to render the molecule incapable of disrupting the AKAP-PKA interaction (35), seems to inhibit PKA (87) . The aim of current research is to design small molecule inhibitors for AKAP-PKA interactions (88, 89) . Intriguingly, it has been reported that the small molecule 3,3'-diamino-4,4'-dihydroxydiphenylmethane (FMP-API-1) and its derivatives inhibit AKAP-PKA interactions in vitro and in cultured cardiomyocytes (88) ( Figure 2C ). As FMP-API-1, however, also activates PKA (88), synthesis of additional small molecules is still warranted. Indeed, new terpyridine scaffolds has been recently synthesized (89) , representing the non-peptidic compounds which might exert less unwanted biological side effects.
Relation to disease
Disturbance of AKAPs either at the level of their expression profile or biological functions has been associated with a variety of diseases (35, 38, 39, 63). For example, AKAP12, also known as AKAP250 or Gravin, was first identified as an auto-antigen in myasthenia gravis (90) . Down regulation of AKAP12 is associated with prostate hyperplasia (91) and several types of cancer (92), including gastric cancer (93). It is tempting to speculate that down regulation of AKAP12 might be mediated by promoter hypermethylation, a mechanism described before in the context of oesophageal and colon cancer (94-96).
Such a mechanism for the promotion of cancer cell invasiveness by AKAP12 (97). In line with this, AKAP12 inhibits cell proliferation (92, 98) . In addition to AKAP12, other members of the AKAP family such as AKAP4 and AKAP9 are discussed as cancer markers (99-104).
In the following sections we will first focus on the compartmentalization of cAMP maintained by AKAPs in the context of neuronal learning and memory processes related to neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and Wallerian degeneration. Then, we will highlight our current knowledge about compartmentalized cAMP signalling networks in the context of obstructive pulmonary diseases such as chronic obstructive pulmonary disease and asthma, and whenever appropriate we will emphasize the effect of AKAPbased multiprotein complexes.
Lessons from neurons and neurodegenerative diseases
In the following sections we will discuss the most recent findings on compartmentalized cAMP signalling to maintain proper neuron functions and to alleviate symptoms of neurodegenerative disease. In particular, we will highlight studies that focus on members of the AKAP family.
Concept of neuronal cAMP compartmentalization: PKA and Epac
Neurons represent highly polarized structures, displaying short, tapered dendrites and long, thin axons (105) (106) (107) . In primary rat hippocampal neurons, Poo and colleagues demonstrated that LKB1 phosphorylation by PKA represents an early event in axonal differentiation, whereas Smurf1 phosphorylation by PKA directs selective neuronal degradation of Par6 or RhoA (106, 108) . In rat dorsal root ganglion neurons, local cAMP levels regulate axonal guidance through the attraction and repulsion of axons, a process involving netrin-1 and myelin-associated glycoprotein (MAG) (109, 110) . High cAMP levels during the embryonic stage regulate axonal guidance by Epac, whereas low cAMP levels during the postnatal stage result in growth cone repulsion by PKA (110) .
Local changes in cAMP determine hippocampus-dependent learning and memory stages such as acquisition, consolidation, retrieval, reconsolidation and extinction (111, 112 In addition, several recent genetic and pharmacological studies report on the role of Epac in a context-dependent fear-conditioning paradigm (118) (119) (120) (121) (122) (123) (124) (125) .
Concept of compartmentalization of cAMP: AKAP5
As outlined earlier, both PKA and Epac seem to sense local changes in cAMP to control neuronal development and differentiation, learning and memory. Compartmentalization of cAMP in the brain seems to be maintained primarily by AKAP5 (126) . AKAP5 is regulated during neuronal development (127) , and provides a platform to integrate neuronal cAMP signalling networks (30). Thus, AKAP5 most likely coordinates the fine tuning of cAMP by regulating the temporal and spatial events controlling cAMP levels.
Indeed, a neuronal cAMP-sensing multiprotein complex maintained by AKAP5, PKA, Epac2 and PKB/Akt, controlled the survival protein kinase B/Akt pathway (30).
AKAP5: Neurotransmission, learning and memory
Binding of PKA to AKAPs alters synaptic protein phosphorylation and thereby controls synaptic plasticity and memory consolidation (126) . In hippocampal neurons, AKAP5
acts as a postsynaptic scaffold protein that also binds to phosphatase 2B/calcineurin (PP2B/CaN; also PPP3) (128) and PKC next to PKA protein (129, 130) AKAP5 directly interacts with the neuronal L-type calcium channel subunit Cav1.2 (137) , and thereby forms a complex with AC, PKA and PP2A, and is, therefore, able to modulate Ca 2+ signalling downstream of the β2-AR (138) . Anchoring of PP2B/CaN to AKAP5 regulates internalization and rapid dephosphorylation of the AMPA
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Chapter 2 receptor, and most likely reflects a form of molecular and cellular memory associated with long-term depression (LTD) ( Figure 3B ) (134) . Indeed, brain slices derived from adult AKAP5 knock-out mice display normal basal hippocampal spine density and synaptic transmission, but exhibit deficiency in LTD, learning and memory (127) .
Malenka and colleagues (139) reported that AKAP5 modulates LTD most likely through binding of AKAP5 to PSD-95, causing the release of PP2B/CaN, and subsequently enhances endocytosis of synaptic AMPA receptors. As a consequence, AKAP5 may leave the spine, and thereby contribute to the shrinkage of spines that accompanies LTD (139). Currently, the best genetic models for studying AKAP5 function are the Δ36 mice, which lack the PKA binding site at the C-terminus of AKAP5 (140), and AKAP5-deficient mice (141). Δ36 mice display both long-term potentiation and LTD defects. In contrast, the AKAP5 deficient mice exhibit only LTD defects. Such differences suggest that the most critical function of AKAP5 is most likely related to its interaction with PKA, to control the formation and/or maintenance of dendritic spines (142). It is clear that regulation of PKA signalling by AKAP5 is necessary to facilitate neurotransmission, learning and defined stages of the memory.
Throughout the mouse brain, AKAP5 is widely distributed in regions linked to learning and memory in rodents, such as the cortex, the hippocampus and the amygdala (126, (143) (144) (145) . Using contextual fear conditioning in mice, the expression of AKAP5 protein was increased in the hippocampus in a late phase of memory consolidation of associative memory (117) . Disruption of hippocampal AKAP-PKA interactions by stHt31 or st-superAKAP-IS facilitates the extinction and impairs the consolidation of contextual fear memories, whereas acquisition and retrieval remain unchanged (30) (Figure 3 ). Disruption of AKAP-PKA interactions by st-Ht31 in the rat lateral amygdala impaired memory consolidation in auditory fear conditioning (126) . Using the Morris water maze to study learning and spatial memory, AKAP5-deficient mice exhibit deficits in spatial memory retention most likely caused by delocalization of PKA and subsequent alterations in the local environment of cAMP signalling in the hippocampus (130) . Taken together, the results from several recent studies illustrate the importance of AKAP5 for maintaining neuronal compartmentalized cAMP signalling to coordinate learning and memory.
AKAP5: Lessons from Alzheimer's disease
As discussed earlier, cAMP in neurons is crucial for learning, memory and physiological events but it is not known how this system is altered under pathological neurodegenerative circumstances. Elucidating this is likely to provide mechanistic insights that may give some clues for the development of novel pharmacological tools.
Ample evidence suggests that perturbation of local cAMP signalling contributes to the development and progression of neurodegenerative diseases. Here we focus on the role of the players discussed previously in the context of Alzheimer's disease.
Alzheimer's disease is a neurodegenerative disease characterized by the progressive decline of cognitive function and memory, and is the fourth largest cause of death for people over 65 years of age (146) . The disease is characterized by extracellular β-amyloid plaques, intracellular neurofibrillary tangles, cholinergic transmission defects and neuronal loss preferentially in the entorhinal cortex and hippocampus (146) . As several inflammatory markers are up-regulated in Alzheimer's disease, it is generally assumed that inflammation is linked to the pathogenesis of Alzheimer's disease. Indeed, amyloid plaques seem to trigger inflammatory processes Table 2) . Even though not yet being studied in detail in the context of neurodegenerative diseases, a central role for the AKAP family member AKAP5 might be envisaged due to its ability to interact with the β2-AR and/or PDE4 (164), and due to its ability to maintain neuronal cAMP compartmentalization. Airway smooth muscle and obstructive pulmonary diseases Another treatment option in obstructive airway diseases is represented by PDE inhibition, for instance the selective PDE4 inhibitors rolipram and roflumilast (187) (188) (189) .
PDE inhibitors increase the cellular level of cAMP by preventing its degradation.
Although both β2-agonists and PDE inhibitors show anti-inflammatory properties in vitro (190) (191) (192) , a notable difference is seen in vivo. PDE4 inhibitors show anti-inflammatory properties in vivo, but largely lack airway smooth muscle relaxing properties. In contrast, β2-agonists show bronchorelaxing properties in vivo, but lack anti-inflammatory properties (187, 193) . Possible explanations for this discrepancy are most likely β2-AR desensitization and/or biased signalling of the β2-AR towards ERK signalling (194, 195) , features largely absent with PDE4 inhibitors due to their post-receptor mode of action.
Both the process of β2-AR desensitization and biased signalling seem to be facilitated by scaffolding proteins such as AKAP5 and AKAP12 (196, 197) (Figure 1 downstream of the β2-AR will most likely circumvent receptor desensitization. One might also expect that such strategies will increase treatment specificity, and thereby minimize unwanted side effects, by targeting only the desired cAMP pool. In the following section, the potential effect of compartmentalized cAMP signalling in the lung for further improvement of obstructive airway diseases will be discussed.
A-kinase anchoring proteins: Signalling in the airway smooth muscle
In the airway smooth muscle, the main signalling pathways that determine its functionality are receptors coupling to Gq or Gs proteins. The Gq protein-coupled receptor family is the M3 muscarinic receptor known to be activated by acetylcholine, and to be inhibited by anticholinergics such as tiotropium (178) . After agonist binding, the Gαq subunit activates phospholipase C (PLC), thereby leading to the elevation in cellular calcium and activation of calcium/calmodulin-dependent myosin light chain (MLC), a process known to result in airway smooth muscle contraction (198, 199) . Activation of PKC by diacylglycerol alters also the (de)phosphorylation of the MLC through several pathways and thereby contributes to the airway smooth muscle tone (198) . Activation of the Gs protein-coupled receptors by drugs targeting the β2-AR, causes elevation of cAMP production via Gs and subsequent activation of ACs (Figure 4) .
Two members of the AKAP superfamily are known to interact with the β2-AR, AKAP5 and AKAP12. Whereas the association of AKAP5 with the β2-AR is constitutive (164, 200) , agonist binding to the β2-AR increases the interaction of the receptor with AKAP12 (201) . Despite the fact that AKAP5 and AKAP12 share many common features, no redundancy is seen between them with regard to this cellular response (197) . AKAP5
has been reported to switch the coupling of the β2-AR from Gs to Gi, a process most likely facilitated by a PKA-mediated phosphorylation of the receptor (164, 200, 202, 203) ( Figure 1) . It has been reported that coupling of the β2-AR to Gi leads to activation of ERK signalling (204) . The ERK pathway is known to be linked to both proliferative and cytokine production pathways in airway smooth muscle (15, 16, 205, 206) . In the context of obstructive pulmonary diseases, it is worthwhile to emphasize reports indicating that AKAP5 seems to determine the cell surface expression of the β2-AR by increasing the affinity of G-protein coupled receptor kinase 2 (GRK2) for βγ subunits of the G-proteins, causing their translocation to the membrane, leading to the desensitization and
44
Chapter 2 internalization of the β2-AR (207) (Figure 1) . In contrast, after desensitization, AKAP12
is essential for the dephosphorylation, resensitization and recycling of the β2-AR back to the cell membrane (197, 201, 204) . In addition, interaction of GRK2 with Ezrin (AKAP78) determines the β2-AR internalization (208) (Figure 1 ). Based on these findings, it is reasonable to assume that β2-AR functions are determined by the balance between AKAP5, AKAP12 and Ezrin (AKAP78) (Figure 1) .
Indeed, a recent study from Penn and colleagues reported on the expression of AKAP5, AKAP12 and Ezrin (AKAP78) in human airway smooth muscle cells (209) . Penn and colleagues did not observe effects of Ht31 or AKAP-IS studying whole cell cAMP after stimulation with isoprenaline or the direct AC activator forskolin. However, using a cyclic nucleotide gated ion channel reporter the authors showed that local cAMP concentrations close to the near-membrane compartment were significantly and transiently increased (209) . Using a combination of st-Ht31 and a PDE inhibitor cocktail, the authors demonstrated that disruption of PKA-AKAP interactions resulted in sustained AC activity (209) . Mathematical models predicted that tethering of PKA to AKAP should cause a threefold increase in PKA at the β2-AR compartment, thereby decreasing input of the β2-AR acting as a negative feedback for AC and PDE activity (209) . Indeed, direct inhibition of PKA with the protein kinase inhibitor (PKI) completely blunted the rapid decay of the cAMP signal over time (209) . With multiple AKAPs possibly involved to create such PKA pool, utilization of tools recently described by Gold et al. (81) would be necessary to assess the individual contribution of each AKAP.
In the following sections we will discuss the role of cAMP compartmentalization in some of the important features of chronic obstructive pulmonary diseases; contraction, inflammation and remodelling. Herein we will keep the focus on studies performed in airway smooth muscle.
A-kinase anchoring proteins: Airway smooth muscle contraction
Elevation of cAMP leads to the activation of both PKA and Epac and thereby modulates airway smooth muscle responses (15, 16) . It is well established that PKA on its own deactivates MLC kinase and desensitizes the IP3 receptor, thereby functionally counteracting the PLC-PKC pathway. In our research group and by others, Epac has been identified as a novel factor being involved in the regulation of airway smooth muscle relaxation. Epac, acting most likely via its main effector Rap1, deactivates RhoA and up-regulates Rac1 activation, causing the balance to shift from phosphorylated MLC to non-phosphorylated MLC and thus to airway smooth muscle relaxation (210, 211) ( Figure 4) . Interestingly, Ezrin (AKAP78) is phosphorylated by Rho-regulated Rho-kinase and binds via its ezrin-radixin-moesin domain the Rho inhibitor Rho guanine-nucleotidedissociation inhibitor (RhoGDI) (212) . Airway smooth muscle cells express both Epac and Ezrin (AKAP78) (209, 213) . Thus deactivation of Rho by Epac might involve mechanisms driven by Ezrin (AKAP78) and RhoGDI.
In a Madin-Darby canine kidney cell line, activated Ezrin (AKAP78) binds in a calcium dependent manner to Rac and thereby delayed membrane localization of Ecadherin (214) . Calcium underlies also cellular compartmentalization and cross-talk with cAMP, a process being facilitated by members of the AKAP family. For example, AKAP5, known to be involved in β2-AR desensitization as outlined earlier (Figure 1) , interacts with calcineurin (215, 216) and calmodulin (217) . Calmodulin competes with PKC in a Ca 2+ -dependent manner for binding to AKAP5 (218) . More recently, AKAP12, known to be involved in β2-AR sensitivity (Figure 1) , rapidly redistributes from the plasma membrane to the cytosol upon stimulation with calcium-elevating agents such ionomycin or thapsigargin (219) . Moreover, it has been reported that AKAP12 displace PKA-RII from the membrane (219).
A striking example of cooperativity between cAMP and calcium facilitated by Results from our research groups and others implicate that such close interconnectivity requires the presence of spatial regulation. AKAP5 was shown to be present in the same AKAP-PKA -Epac complex described before in neuronal cells (30).
In a related study, we showed that induction of IL-8 release by cigarette smoke extract (CSE) was attenuated by the β2-agonist fenoterol, seemingly via Epac and PKA (222) .
Disturbance of AKAP-based multiprotein complexes might be expected due to the down regulation of Epac1 and members of the AKAP family by CSE (222, 223) . Indeed, AKAP12 is down regulated in lung cancer (224) . With AKAP5 and AKAP12 known to determine β2-AR functions (Figure 1) , an important role for PKA and Epac localization close to G protein-coupled receptors in asthma and COPD could be imagined. This could explain the varying treatment outcomes seen for these bronchodilators in COPD (184) (185) (186) . Interestingly, AKAP11 was found to be expressed in airway smooth muscle using realtime PCR (209). AKAP11 is not only able to bind PKA, but also GSK3, a kinase shown 48 Chapter 2 to be involved in expression of contractile proteins in airway smooth muscle (233) , their proliferation (234, 235) and profibrotic signalling (236) . Thus, AKAP11 driven cAMP compartmentalization may regulate airway smooth muscle remodelling.
In summary, several lines of evidence point towards the logical conclusion that AKAP family members are most likely of key importance for cAMP compartmentalization and thereby signalling to maintain a fine-tuned control over structural lung cell responses. Future studies will surely add additional insights into our current knowledge of signal compartmentalization and perhaps cross-talk between calcium and cAMP in the lung.
Outlook and Future perspectives
Compartmentalization of cAMP by AKAP family members represents a highly specialized and dynamic process to fine-tune intracellular signalling. Disturbance of cAMP compartmentalization, either due to alterations in AKAP expression or complex composition with a variety of tools outlined herein, seems to profoundly regulate biological functions and thereby to contribute to neurodegenerative and obstructive lung diseases.
Aging of the worldwide population will require further improvement of the management of chronic diseases. Notably, cAMP and its effectors seem to be critical in regulating several processes both in chronic brain and lung diseases. Next to PKA, Epac seems to act as a novel pharmacological target in both groups of diseases; however, the impact of Epac compared with PKA might be diverse and sometimes even conflicting.
Members of the AKAP superfamily maintain cellular compartmentalization of cAMP primarily via direct interaction with PKA, a process now also linked to Epac. As AKAP bearing multiprotein complexes regulate receptor desensitization and are able to target simultaneously cAMP and calcium, the AKAP superfamily most likely represent an interesting novel pharmacological concept. In chronic obstructive pulmonary disease, targeting calcium-mediated bronchoconstriction and cAMP-mediated bronchorelaxation by one AKAP related drug might give an additional benefit above the current combination therapy with anticholinergics and β2-agonists (237).
As outlined herein, the design of small molecule inhibitors seems to represent one of the most recent key findings in the field of AKAP research (88, 89) . The AKAP-PKA interaction has been also used as a template for drug design based on the 'Dockand-Lock Method' (238, 239) . Here, a trivalent drug is created upon conjugation of two identical (pro-)drugs (e.g. interferon-alpha 2b (240) 54
